Effects of dietary inulin, statin, and their co-treatment on hyperlipidemia, hepatic steatosis and changes in drug-metabolizing enzymes in rats fed a high-fat and high-sucrose diet

Nutrition and Metabolism

Volumn 9, Issue , 2012, Pages

  Sugatani, Junko ^a   Sadamitsu, Satoshi ^a   Wada, Tadashi ^b   Yamazaki, Yasuhiro ^a   Ikari, Akira ^a   Miwa, Masao ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b Fuji Nihon Seito Corporation   (Japan)

Author keywords

CYP1A1 2; CYP2E1; Fluvastatin; Hepatic steatosis; Lipid lowering drug; Synthetic inulin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; ETHOXYRESORUFIN DEETHYLASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INULIN; SUCROSE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; FATTY LIVER; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID DIET; MALE; NONHUMAN; RAT; WHITE ADIPOSE TISSUE;

RATTUS;

EID: 84858802407     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-9-23     Document Type: Article

References (38)

1. The induction of a specific form of cytochrome P450 (P450j) by fasting. Hong J, Pan J, Gonzalez FJ, Gelboin HV, Yang CS, Biochem Biophys Res Commun 1987 142 1077 1088 10.1016/0006-291X(87)91525-7 3827895 (Pubitemid 17021143)
2. Ethanol-, fasting-, and acetone-inducible cytochromes P450 in rat liver: Regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies. Johansson I, Ekstrom G, Scholte B, Puzycki D, Jornvall H, Ingelman-Sundberg M, Biochemistry 1988 27 1925 1934 10.1021/bi00406a019 3378038
3. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Weltman MD, Farrell GC, Liddle C, Gastroenterology 1996 111 1645 1653 10.1016/S0016-5085(96)70028-8 8942745 (Pubitemid 26404230)
4. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepayitis. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR, J Clin Invest 2000 105 1067 1075 10.1172/JCI8814 10772651 (Pubitemid 30217691)
5. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Emery M, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, Thummel KE, Hepatology 2003 38 428 435 12883487 (Pubitemid 36919864)
6. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW, Hepatology 2003 37 544 550 10.1053/jhep.2003. 50095 12601351 (Pubitemid 36258775)
7. Does hepatic steatosis affect drug metabolizing enzymes in the liver? Buechler C, Weiss TS, Curr Drug Metab 2011 12 24 34 10.2174/138920011794520035 21222589
8. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Fisher CD, Lickyeig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferquson SS, Cherrington NJ, Drug Metab Dispos 2009 37 2087 2094 10.1124/dmd.109.027466 19651758
9. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Weltman MD, Farrell GC, Hall P, Incelman-Sundberc M, Liddle C, Hepatology 1998 27 128 133 10.1002/hep.510270121 9425928 (Pubitemid 28041545)
10. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Chtioui H, Semeia D, Ledermann M, Zimmermann A, Dufour JF, Liver Int 2007 27 764 771 10.1111/j.1478-3231.2007. 01524.x 17617119 (Pubitemid 47062043)
11. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M, Gastroenterology 2002 123 134 140 10.1053/gast.2002. 34168 12105842 (Pubitemid 34747534)
12. Resistent starch is more effective than cholestyramine as lipid-lowering agent in the rat. Younes H, Levrat MA, Demigne C, Remesy C, Lipids 1995 30 847 853 10.1007/BF02533961 8577229
13. Dietary oligofructose lessens hepaticc steatosis, but does not prevent hypertriglyceridemia in obese Zucker rats. Daubioul CA, Taper HS, De Wispelaere LD, Nathalie MD, J Nutr 2000 130 1314 1319 10801936 (Pubitemid 30233286)
14. The water-soluble extract of chicory influences serum and liver lipid concentrations, cecal short-chain fatty acid concentrations and fecal lipid excretion in rats. Kim M, Shin HK, J Nutr 1998 128 1731 1736 9772143 (Pubitemid 28452859)
15. Physicochemical characterization and biological effects of inulin enzymatically synthesized from sucrosae. Wada T, Sugatani J, Terada E, Ohguchi M, Miwa M, J Agric Food Chem 2005 53 1246 1253 10.1021/jf048711u 15713048 (Pubitemid 40270423)
16. High propionic acid fermentations and mineral accumulation in the cecum of rats adapted to different levels of inulin. Levrat M-A, Remesy C, Demigne C, J Nutr 1991 121 1730 1737 1941180
17. Comparison of enzymatically synthesized inulin, resistant maltodextrin and clofibrate effects on biomarkers of metabolic disease in rats fed a high-fat and high sucrose (cafeteria) diet. Sugatani J, Osabe M, Wada T, Yamakawa K, Yamazaki Y, Takahashi T, Ikari A, Miwa M, Eur J Nutr 2008 47 192 200 10.1007/s00394-008-0713-z 18560790
18. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferators-activated receptor a in male rats fed a high-fat and high-sucrose diet. Osabe M, Sugatani J, Fukuyama T, Ikushiro S, Ikara A, Miwa M, Drug Metab Dispos 2008 36 294 302 10.1124/dmd.107.017731 17967931 (Pubitemid 351185741)
19. Dietary inulin alleviates hepatic steatosis and xenobiotics-induced liver injury in rats fed a high-fat and high-sucrose diet association with the suppression of hepatic cytochrome P450 and hepatocyte nuclear factor 4a expression. Sugatani J, Wada T, Osabe M, Yamakawa K, Yoshinari K, Miwa M, Drug Metab Dispos 2006 34 1677 1687 10.1124/dmd.106.010645 16815962 (Pubitemid 44427470)
20. Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats. Sugatani J, Sadamitsu S, Kurosawa M, Ikushiro S, Sakaki T, Ikari A, Miwa M, Drug Metab Dispos 2010 38 1655 1664 10.1124/dmd.110.034090 20587623
21. Dual activation of PPARalpha and PPARgamma by mono-(2-ethylhexyl) phthalate in rat ovarian granulose cells. Lovekamp-Swan T, Jetten AM, Davis BJ, Mol Cell Endocrinol 2003 201 133 141 10.1016/S0303-7207(02)00423-9 12706301 (Pubitemid 36434289)
22. Cytochromes P4501 (CYP1): Catalytic activities and inducibility by diesel exhaust particle extract and benzo[a]pyrene in intact human lung ex vivo. Iba MM, Shin M, Caccavale RJ, Toxicol 2010 273 35 44 10.1016/j.tox.2010.04.012
23. A preliminary report on the feeding of cynomolgus monkeys (Macaca fascicularis) with a high-sugar high-fat diet for 33 weeks. Mubiru JN, Forey MG, Higgins PB, Hemmat P, Cavazos NE, Dick EJ Jr, Owston MA, Bauer CA, Shade RE, Comuzzie AG, Rogers J, J Med Primatol 2011 40 335 341
24. Insulin differentially affects xenobiotic-enhanced cytochrome P-450 (CYP) 2E1, CYP2B, CYP3A, and CYP4A expression in primary cultured rat hepatocytes. Woodcroft KJ, Novak RF, J Pharmacol Exp Ther 1999 289 1121 1127 10215695 (Pubitemid 29191274)
25. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Emery M, Fisher JM, Chien JY, Kharasch ED, Dellinger EP, Kowdley KV, Thummel KE, Hepatology 2003 38 428 435 12883487 (Pubitemid 36919864)
26. Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor, and the cofactor peroxisome proliferators-activated receptor coactivator-1 Ding X, Lichti K, Kim I, Gonzalez FJ, Staudinger H, J Biol Chem 2006 281 26540 26551 10.1074/jbc.M600931200 16825189 (Pubitemid 44401863)
27. Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. Demigne C, Morand C, Levrat MA, Besson C, Moundras C, Remesy C, Br J Nutr 1995 74 209 219 10.1079/BJN19950124 7547838
28. Effects of propionate on lipid biosynthesis in isolated rat hepatocytes. Nishina PM, Freedland RA, J Nutr 1990 120 668 673 2366102 (Pubitemid 20228447)
29. The regulation of cytochromeP450 2E1 during LPS-induced inflammation in the rat. Abdulla D, Goralski KB, Renton KW, Toxicol Appl Pharmacol 2006 216 1 10 10.1016/j.taap.2006.03.012 16712892 (Pubitemid 44402628)
30. Post-transcriptional regulation of rat CYP2E1 expression: Role of CYP2E1 mRNA untranslated regions in control of translational efficiency and message stability. Kocarek TA, Zangar RC, Novak RF, Arch Biochem Biophys 2000 376 180 190 10.1006/abbi.2000.1704 10729204 (Pubitemid 30205128)
31. Summary of information on human CYP enzymes: Human P450 metabolism data. Rendic S, Drug Metab Rev 2002 34 83 448 10.1081/DMR-120001392 11996015 (Pubitemid 34311090)
32. Thiomethylstilbenes as inhibitors of CYP1A1, CYP1A2 and CYP1B1 activities. Mikstacka R, Baer-Dubowska W, Wieczorek M, Sobiak S, Mol Nutr Food Res 2008 52 77 83
33. Induction of cytochrome P4501A1. Whitlock JP Jr, Annu Rev Pharmacol 1999 39 103 125 10.1146/annurev.pharmtox.39.1.103 (Pubitemid 29222553)
34. Insights into the structure, function, and regulation of human cytochrome P450 1A2. Zhou SF, Chan E, Zhou ZW, Xue CC, Lai X, Duan W, Curr Drug Metab 2009 10 713 729 10.2174/138920009789895552 19702529
35. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Gunes A, Dahl ML, Pharmacogenomics 2008 9 625 637 10.2217/14622416.9.5.625 18466106 (Pubitemid 351803920)
36. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Murray M, Current Drug Metab 2006 7 67 81 10.2174/138920006774832569
37. Sulfur dioxide and benzo(a)pyrene modulates CYP1A and tumor-related gene expression in rat liver. Qin G, Meng Z, Environ Toxicol 2009 25 169 179
38. A novel synthetic analogue of a constituent of lsodon excisus inhibits transcription of CYP1A1,-1A2 and -1B1 by preventing activation of the aryl hydrocarbon receptor. Sienkiewicz P, Ciolino HP, Leslie BJ, Hergenrother PJ, Singletary K, Yeh GC, Carcinogenesis 2007 28 1052 1057 17183067 (Pubitemid 47072190)